期刊
JOURNAL OF CONTROLLED RELEASE
卷 338, 期 -, 页码 804-812出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2021.08.051
关键词
Pegloticase; PEG; Anti-PEG antibodies
资金
- David and Lucile Packard Foundation [2013-39274]
- National Institutes of Health [T32HL069768, R01 HL141934]
- P.E.O. International
- Eshelman Institute of Innovation
- NCI [P30-CA016086]
- NIH shared instrumentation grant [1S10OD023611]
Pre-infusion of high MW free PEG (40 kDa) can serve as a decoy to saturate circulating APA, preventing subsequent doses of pegloticase from being eliminated from the circulation rapidly by APA. This strategy may offer a promising approach to enable safe and effective use of pegloticase in patients with treatment-refractory gout who have developed anti-PEG antibodies.
Pegloticase is an enzyme used to reduce serum uric acid levels in patients with chronic, treatment-refractory gout. Clinically, about 40% of patients develop high titers of anti-PEG antibodies (APA) after initial treatment, which in turn quickly eliminate subsequent doses of pegloticase from the systemic circulation and render the treatment ineffective. We previously found that pre-infusion with high MW free PEG (40 kDa) can serve as a decoy to saturate circulating APA, preventing binding to a subsequently administered dose of PEG-liposomes and restoring their prolonged circulation in mice, without any detectible toxicity. Here, we investigated the use of 40 kDa free PEG to restore the circulation of radio-labeled pegloticase in mice using longitudinal Positron Emission Tomography (PET) imaging over 4 days. Mice injected with pegloticase developed appreciable APA titers by Day 9, which further increased through Day 14. Compared to naive mice, mice with pegloticase-induced APA rapidly cleared 89Zr-labeled pegloticase, with -75% lower pegloticase concentrations in the circulation at four hours after treatment. The 96-h AUC in APA+ mice was less than 30% of the AUC in naive mice. In contrast, preinfusion of free PEG into PEG-sensitized mice restored the AUC of pegloticase to -80% of that seen in naive mice, resulting in a similar biodistribution to pegloticase in naive mice over time. These results suggest that preinfusion of free PEG may be a promising strategy to enable the safe and efficacious use of pegloticase and other PEGylated drugs in patients that have previously failed therapy due to induced APA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据